Anish Patel Sells 17,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 17,500 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $25.03, for a total value of $438,025.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Anish Patel also recently made the following trade(s):

• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.60, for a total value of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.64, for a total value of $76,245.00.
• On Tuesday, February 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.11, for a total value of $73,661.25.
• On Monday, January 22nd, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.13, for a total value of $73,758.75.

Enliven Therapeutics Stock Down 6.3 %

Shares of ELVN stock opened at $18.69 on Wednesday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The business’s 50 day moving average is $16.94 and its two-hundred day moving average is $14.29. The company has a market cap of $770.03 million, a PE ratio of -8.53 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC grew its holdings in Enliven Therapeutics by 1.8% during the fourth quarter. Citadel Advisors LLC now owns 2,394,448 shares of the company’s stock valued at $33,139,000 after purchasing an additional 42,782 shares during the last quarter. BlackRock Inc. boosted its position in shares of Enliven Therapeutics by 4,476.0% in the second quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock valued at $31,564,000 after acquiring an additional 1,512,680 shares during the period. Vanguard Group Inc. boosted its position in shares of Enliven Therapeutics by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 1,230,888 shares of the company’s stock valued at $17,035,000 after acquiring an additional 79,071 shares during the period. State Street Corp boosted its position in shares of Enliven Therapeutics by 4,847.5% in the second quarter. State Street Corp now owns 466,251 shares of the company’s stock valued at $9,516,000 after acquiring an additional 456,827 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Enliven Therapeutics by 1,071.1% in the second quarter. Geode Capital Management LLC now owns 414,444 shares of the company’s stock valued at $8,459,000 after acquiring an additional 379,056 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.